8-K filing — MiNK Therapeutics, Inc. (INKT)
Filed: 2026-08-13 AccNo: 0001193125-26-347907 Size: 215 KB Item 2.02: Results of Operations and Financial Condition
Read original at edgarStocks · News reference
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:29 PM
- Checked
- Aug 13, 2026, 1:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug Consulting
Read original at benzingaMiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor Liberation
Read original at benzinga